ERBB2 and inflammatory breast carcinoma: We applied Firth logistic regression adjusted for hormonal receptor status (positive vs negative), HER2 status (positive vs negative), stage (II vs I, III vs I, IV vs I) and cohort (MSK-IMPACT vs MBC) with genomic alterations or metastatic sites as outcome variables and IBC status as independent variable (yes vs no).